Rheumatology Advisor Contributing Writer

The research design of RA BIODAM and study population’s clinical characteristics over 2 years of follow-up were published in an initial report.

Researchers assessed nationally endorsed performance measures for rheumatoid arthritis care using population-based administrative data.

The majority of patients with rheumatoid arthritis-associated bronchiectasis treated with rituximab have a satisfactory safety profile.

The modified DAS28 with C-reactive protein is a strong predictor of rapid radiographic progression in patients with early rheumatoid arthritis.

Noninferiority trials do not provide direct evidence of superiority to placebo but can provide evidence to support efficacy of RA therapies.

Clinicians should be aware that patients with RA who develop ESRD are at risk of experiencing cardiac events sooner than patients in the general population.

Study location, patient population, and background treatment may affect American College of Rheumatology placebo response rates in clinical trials for rheumatoid arthritis.

The use of tumor necrosis factor inhibitors is associated with an increased risk for incident neuroinflammatory disease in patients with psoriatic arthritis and ankylosing spondylitis but not in patients with rheumatoid arthritis.